🟢 Lipocine is trading 6.13% up today following Q2 results and board appointment

Lipocine is trading at $2.26 (+6.13%) after reporting second-quarter 2026 results and announcing a key addition to its board of directors.

• The company reported Q2 revenue of $190,099, down from $622,849 a year earlier, though investors appear focused on corporate developments rather than the top-line decline.
• Michael J. Grissinger joined the board effective August 3, as the company continues to progress its LPCN 1154 program following earlier clinical setbacks.
• The stock's advance is supported by a strong biotech tape, with the XBI up 2.02% amid constructive risk sentiment across the sector.